Global Sedation Drugs and Companies Pipeline Review H2 2016



Sedation Therapeutic Pipeline Market Review, H2 2016

PUNE, INDIA, September 1, 2016 / -- Summary
Sedation - Pipeline Review, H2 2016’, provides an overview of the Sedation pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Sedation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sedation and features dormant and discontinued projects.

Complete report details @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @

- The report provides a snapshot of the global therapeutic landscape of Sedation
- The report reviews pipeline therapeutics for Sedation by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Sedation therapeutics and enlists all their major and minor projects
- The report assesses Sedation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Sedation
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sedation
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sedation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sedation Overview 7
Therapeutics Development 8
Pipeline Products for Sedation - Overview 8
Sedation - Therapeutics under Development by Companies 9
Sedation - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Sedation - Products under Development by Companies 13
Sedation - Companies Involved in Therapeutics Development 14
AstraZeneca Plc 14
Drawbridge Pharmaceuticals Pty Ltd 15
Jiangsu Nhwa Pharmaceutical Corporation Ltd. 16
NanoMedex Pharmaceuticals, Inc. 17
Paion AG 18
Primex Pharmaceuticals Oy 19
The Medicines Company 20
Therakind Limited 21
Sedation - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 30
ABP-700 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ADV-6209 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
alphaxalone - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
clonidine hydrochloride - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
EL-001 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
propofol - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
propofol microemulsion - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
remimazolam - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecule to Agonize GABA-A for Sedation - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Sedation - Dormant Projects 46
Sedation - Discontinued Products 47
Sedation - Product Development Milestones 48
Featured News & Press Releases 48
Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy 48
Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy 49

Buy this report @

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here